Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1991 1
1992 2
1993 1
1997 1
1999 2
2000 1
2001 1
2002 1
2003 1
2004 1
2006 4
2007 5
2008 4
2009 2
2010 1
2011 1
2021 3
2022 0
Text availability
Article attribute
Article type
Publication date

Search Results

29 results
Results by year
Filters applied: . Clear all
Page 1
Discovery of TAK-041: a Potent and Selective GPR139 Agonist Explored for the Treatment of Negative Symptoms Associated with Schizophrenia.
Reichard HA, Schiffer HH, Monenschein H, Atienza JM, Corbett G, Skaggs AW, Collia DR, Ray WJ, Serrats J, Bliesath J, Kaushal N, Lam BP, Amador-Arjona A, Rahbaek L, McConn DJ, Mulligan VJ, Brice N, Gaskin PLR, Cilia J, Hitchcock S. Reichard HA, et al. Among authors: schiffer hh. J Med Chem. 2021 Aug 12;64(15):11527-11542. doi: 10.1021/acs.jmedchem.1c00820. Epub 2021 Jul 14. J Med Chem. 2021. PMID: 34260228
Development of CVN424: A Selective and Novel GPR6 Inverse Agonist Effective in Models of Parkinson Disease.
Brice NL, Schiffer HH, Monenschein H, Mulligan VJ, Page K, Powell J, Xu X, Cheung T, Burley JR, Sun H, Dickson L, Murphy ST, Kaushal N, Sheardown S, Lawrence J, Chen Y, Bartkowski D, Kanta A, Russo J, Hosea N, Dawson LA, Hitchcock SH, Carlton MB. Brice NL, et al. Among authors: schiffer hh. J Pharmacol Exp Ther. 2021 Jun;377(3):407-416. doi: 10.1124/jpet.120.000438. Epub 2021 Apr 1. J Pharmacol Exp Ther. 2021. PMID: 33795395
First-Time Disclosure of CVN424, a Potent and Selective GPR6 Inverse Agonist for the Treatment of Parkinson's Disease: Discovery, Pharmacological Validation, and Identification of a Clinical Candidate.
Sun H, Monenschein H, Schiffer HH, Reichard HA, Kikuchi S, Hopkins M, Macklin TK, Hitchcock S, Adams M, Green J, Brown J, Murphy ST, Kaushal N, Collia DR, Moore S, Ray WJ, English NM, Carlton MBL, Brice NL. Sun H, et al. Among authors: schiffer hh. J Med Chem. 2021 Jul 22;64(14):9875-9890. doi: 10.1021/acs.jmedchem.0c02081. Epub 2021 Apr 16. J Med Chem. 2021. PMID: 33861086
A quantitative method to detect RNA editing events.
Schiffer HH, Heinemann SF. Schiffer HH, et al. Anal Biochem. 1999 Dec 15;276(2):257-60. doi: 10.1006/abio.1999.4369. Anal Biochem. 1999. PMID: 10603250 No abstract available.
Pharmacology of polymorphic variants of the human 5-HT1A receptor.
Del Tredici AL, Schiffer HH, Burstein ES, Lameh J, Mohell N, Hacksell U, Brann MR, Weiner DM. Del Tredici AL, et al. Among authors: schiffer hh. Biochem Pharmacol. 2004 Feb 1;67(3):479-90. doi: 10.1016/j.bcp.2003.09.030. Biochem Pharmacol. 2004. PMID: 15037200
Broad modulation of neuropathic pain states by a selective estrogen receptor beta agonist.
Piu F, Cheevers C, Hyldtoft L, Gardell LR, Del Tredici AL, Andersen CB, Fairbairn LC, Lund BW, Gustafsson M, Schiffer HH, Donello JE, Olsson R, Gil DW, Brann MR. Piu F, et al. Among authors: schiffer hh. Eur J Pharmacol. 2008 Aug 20;590(1-3):423-9. doi: 10.1016/j.ejphar.2008.05.015. Epub 2008 May 23. Eur J Pharmacol. 2008. PMID: 18559275
29 results